Clinical Studies of Fluticasone Propionate Aerosol (3rd Report)

Study in Vasomotor Rhinitis

Abstract

To patients with vasomotor rhinitis, Fluticasone Propionate (FP) Aerosol was administered in the dose of 200mcg/day for at least 2 weeks in principle, and for 16 weeks at most, to evaluate its clinical efficacy and safety, and the following results were obtained.
1. The total number of the cases receiving the drug was 72.
2. In the assessment of final overall improvement, cases assessed as “markedly improved” plus “moderately improved” accounted for 73.1%, and cumulative rate with “slightly improved” cases added was 88.5%, both rating high.
3. No adverse event was observed in any case. Although there were abnormal values in clinical laboratory tests in 4 cases, they were all of slight nature.
Based on the above results, FP Aerosol was confirmed to be an effective and safe drug also for treatment of vasomotor rhinitis.